Scientists publish discovery of novel protein associated with schizophrenia
Study results from scientists at AstraZeneca and the Lieber Institute for Brain Development indicate that the discovery of a recently evolved protein could lead to new targets for neuropsychiatric disorders and novel treatments for patients.
AstraZeneca launches integrated genomics approach to drug discovery and development
AstraZeneca and its global biologics research and development arm, MedImmune, today announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline.
AstraZeneca presents DNA Damage Response science at the AACR 2016 Annual Meeting
AstraZeneca has announced new data from multiple molecules in its industry-leading DNA Damage Response (DDR) pipeline at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting
AstraZeneca and its global biologics research and development arm, MedImmune, will present 57 abstracts, deliver five oral presentations and two lectures as well as participating in a round-table session on PD-L1 diagnostic harmonisation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans this week.
AstraZeneca and Eli Lilly continue clinical trial for people with early Alzheimer’s disease
AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial.
Brilique approved in EU for extended treatment of patients with history of heart attack
AstraZeneca today announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
AstraZeneca and MedImmune enter consortium to find new treatments for chronic kidney disease
AstraZeneca and its global biologics research and development arm, MedImmune, announced that they have entered into a collaboration with the University of Michigan and Eli Lilly to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD).
AstraZeneca and MedImmune launch 'Science in pictures' artwork project at Cambridge site
AstraZeneca and MedImmune, the global biologics research and development arm of AstraZeneca, this week inaugurated “Science in pictures”, an artwork installation on the hoardings around the construction site of their new Research and Development Centre and Corporate Headquarters on the Cambridge Biomedical Campus.
AstraZeneca and Moderna Therapeutics announce new collaboration
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics have announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
AstraZeneca acquires Takeda’s respiratory business
AstraZeneca today announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
AstraZeneca to harness power of the Secretome and develop next-generation biologics
AstraZeneca and its global biologics research and development arm, MedImmune, today announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome - research into all proteins that…
AstraZeneca expands technological investment in new Cambridge lead discovery centre
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge…
AstraZeneca acquires ZS Pharma
AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California. The acquisition strengthens AstraZeneca's Cardiovascular and Metabolic disease portfolio.
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
AstraZeneca and Eli Lilly and Company (Lilly) have announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumours.
AstraZeneca opens new manufacturing facility to support continued growth in Russia
AstraZeneca today announced the opening of its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer.
AstraZeneca to invest £11.5 million in collaboration with The University of Manchester
AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.
AstraZeneca and Valeant Pharmaceuticals to partner on psoriasis treatment
AstraZeneca announced that it has entered into a collaboration agreement with Valeant Pharmaceuticals International, Inc. under which it will grant an exclusive licence for Valeant to develop and commercialise brodalumab.
AstraZeneca appoints Dr Sean Bohen
AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
AstraZeneca and Peregrine to collaborate on immuno-oncology combination clinical trial
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736).
AstraZeneca and Heptares Therapeutics enter agreement for immuno-oncology treatment
AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor…
AstraZeneca and Isis Pharmaceuticals colaborate to discover and develop antisense drugs
AstraZeneca and Isis Pharmaceuticals, Inc. have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.
US FDA approves AstraZeneca product for non-small cell lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved IRESSA (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
AstraZeneca-University of Cambridge announce joint PhD and clinical research scholarships
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years, spanning translational science, basic and clinical research.